BioCentury
ARTICLE | Clinical News

Novo's semaglutide meets Phase III endpoint

July 11, 2015 12:25 AM UTC

Novo Nordisk A/S (CSE:NVO; NYSE:NV) said once-weekly doses of subcutaneous semaglutide met the primary endpoint in the Phase IIIa SUSTAIN 1 trial to treat Type II diabetes in treatment-naive patients.

In the 388-patient trial, both doses of the long-acting human glucagon-like peptide-1 (GLP-1) analog improved HbA1c from baseline vs. placebo, the study's primary endpoint. At 30 weeks, patients receiving 0.5 mg semaglutide had HbA1c improvements of 1.5% and the 1 mg group had a 1.6% improvement compared with no change in the placebo group. Patients' mean baseline levels were 8.1%. In addition, 74% of patients receiving the low dose and 73% receiving the high dose had HbA1c levels below 7%, vs. 25% of those receiving placebo. ...